Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Wibke Deisting"'
Autor:
Ameya Harmalkar, Roshan Rao, Yuxuan Richard Xie, Jonas Honer, Wibke Deisting, Jonas Anlahr, Anja Hoenig, Julia Czwikla, Eva Sienz-Widmann, Doris Rau, Austin J. Rice, Timothy P. Riley, Danqing Li, Hannah B. Catterall, Christine E. Tinberg, Jeffrey J. Gray, Kathy Y. Wei
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTOver the last three decades, the appeal for monoclonal antibodies (mAbs) as therapeutics has been steadily increasing as evident with FDA’s recent landmark approval of the 100th mAb. Unlike mAbs that bind to single targets, multispecific bi
Externí odkaz:
https://doaj.org/article/f28435022c594bb495320039c11e0b93
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0141669 (2015)
Bispecific T cell engager (BiTE®) are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells. They can elicit a polyclonal cytotoxic T cell response that is not restricted by T cell
Externí odkaz:
https://doaj.org/article/5e250f9fc2434f48aba39a05af53a104
Autor:
Tod Harper, Amy Sharma, Sarav Kaliyaperumal, Flordeliza Fajardo, Katie Hsu, Lily Liu, Rhian Davies, Yu-Ling Wei, Jinghui Zhan, Juan Estrada, Majk Kvesic, Lisa Nahrwold, Wibke Deisting, Marc Panzer, Keegan Cooke, Hervé Lebrec, Olivier Nolan-Stevaux
Publikováno v:
Toxicological Sciences. 189:32-50
Bispecific T-cell engager (BiTE) molecules have great potential to treat cancer. Nevertheless, dependent on the targeted tumor antigen, the mechanism of action that drives efficacy may also contribute to on-target/off-tumor toxicities. In this study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774f0bed25671619c33c61ea448cae63
https://doi.org/10.1093/toxsci/kfac052
https://doi.org/10.1093/toxsci/kfac052
Autor:
Ameya Harmalkar, Roshan Rao, Jonas Honer, Wibke Deisting, Jonas Anlahr, Anja Hoenig, Julia Czwikla, Eva Sienz-Widmann, Doris Rau, Austin Rice, Timothy P. Riley, Danqing Li, Hannah B. Catterall, Christine E. Tinberg, Jeffrey J. Gray, Kathy Y. Wei
Over the last three decades, the appeal for monoclonal antibodies (mAbs) as therapeutics has been steadily increasing as evident with FDA’s recent landmark approval of the 100th mAb. Unlike mAbs that bind to single targets, multispecific biologics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b3aad643c74f4e957cce72de0e34d15
https://doi.org/10.1101/2022.06.03.494724
https://doi.org/10.1101/2022.06.03.494724
Publikováno v:
European journal of nuclear medicine and molecular imaging. 35(6)
In radioiodine therapy the "stunning phenomenon" is defined as a reduction of radioiodine uptake after diagnostic application of (131)I. In the current study, we established an in vitro model based on the "Fisher rat thyrocyte cell line no. 5" (FRTL-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9fdf74f3a101c88618d1fc1ae0c71f9
https://pubmed.ncbi.nlm.nih.gov/18228019
https://pubmed.ncbi.nlm.nih.gov/18228019
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 10, p e0141669 (2015)
PLoS ONE, Vol 10, Iss 10, p e0141669 (2015)
Background Bispecific T cell engager (BiTE®) are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells. They can elicit a polyclonal cytotoxic T cell response that is not restricte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::919f521a5e90186a4529b303fda5631f
https://doi.org/10.1371/journal.pone.0141669
https://doi.org/10.1371/journal.pone.0141669
Autor:
B. E. Wenzel, Roger Nadrowitz, Birgit Meller, Wibke Deisting, Manfred Baehre, Eckart Richter, Johannes Meller, Annette Pethe
Publikováno v:
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 182(1)
Radioiodine uptake (RIU) is one of the main prognostic factors for curative results of radioiodine therapy in patients with differentiated thyroid cancer. Some days after application of (131)I, the uptake of a subsequent administration of radioiodine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5aaccfc3029679f608e74e0ce16ee85
https://pubmed.ncbi.nlm.nih.gov/16404518
https://pubmed.ncbi.nlm.nih.gov/16404518
Publikováno v:
Cancer Research. 73:4734-4734
BiTE antibodies are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells. They are capable of temporarily mounting a polyclonal T cell response that is not restricted by T cell rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5705d641d599962c8ddef844cce6bce
https://doi.org/10.1158/1538-7445.am2013-4734
https://doi.org/10.1158/1538-7445.am2013-4734
Autor:
Birgit Meller, Wibke Deisting, Björn Wenzel, Annette Pethe, Roger Nadrowitz, Johannes Meller, Eckart Richter, Manfred Baehre
Publikováno v:
Strahlentherapie und Onkologie; Jan2006, Vol. 182 Issue 1, p30-36, 7p